MFG-E8 Protein Clearance of Apoptotic Cells in Ischemia Reperfusion Injury

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for ischemia/reperfusion injuries, such as intestinal ischemia/reperfusion and acute lung injury, are limited in effectiveness, leading to significant morbidity and mortality due to inadequate clearance of apoptotic cells and excessive inflammation.

Innovation Solution

Administration of milk fat globule epidermal growth factor-factor VIII (MFG-E8) to enhance apoptotic cell clearance and reduce inflammation, formulated in pharmaceutical compositions for prevention and treatment of organ injury after ischemia/reperfusion events.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional pharmacologic treatments targeting inflammatory mediators and oxidative stress pathways are used, then some benefit in ischemia/reperfusion and acute lung injury is achieved, but the treatments are limited in effectiveness and do not adequately clear apoptotic cells

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidaccumulation of apoptotic cells

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses MFG-E8 as an intermediary molecule that bridges apoptotic cells and phagocytes. MFG-E8 binds to phosphatidylserine on apoptotic cell surfaces and facilitates their recognition and clearance by phagocytes, thereby resolving the accumulation of apoptotic cells that conventional treatments fail to address

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent extracts and targets the specific function of apoptotic cell clearance, which is overlooked by conventional treatments. By focusing solely on enhancing phagocytosis of apoptotic cells through MFG-E8 administration, the patent addresses a specific harmful effect (apoptotic cell accumulation) that separates from the general anti-inflammatory approach

Inventive Principle:

Principle #2Taking out (Extraction)

2Speed

If ischemia/reperfusion occurs, then blood supply returns to tissue after a period of ischemia, but this causes tissue damage through excessive inflammation and apoptotic cell death

Engineering Contradiction:

Improverestoration of blood supplyVSAvoidinflammation and organ injury

Core Design Contradiction:

SpeedVSObject-affected harmful factors

Solution Approach 1:

The patent administers MFG-E8 at the time of reperfusion to preliminarily enhance apoptotic cell clearance before excessive inflammation can fully develop. This preliminary action prevents the harmful effects of inflammation and organ injury that would otherwise result from uncleared apoptotic cells

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the harmful accumulation of apoptotic cells into a beneficial process by using MFG-E8 to facilitate their rapid clearance. The apoptotic cells, which would normally cause inflammation and tissue damage, are instead efficiently removed by phagocytes through MFG-E8-mediated recognition, transforming a harmful effect into a protective mechanism

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

MFG-E8 effectively attenuates organ injury, suppresses systemic inflammatory responses, and improves survival by promoting the clearance of apoptotic cells and reducing cytokine levels, thereby mitigating the severity of ischemia/reperfusion-induced damage.

Implementation Method 1

Apoptotic cells expose phosphatidylserine (PS) that can be recognized by soluble molecules and receptors, thereby enabling their phagocytosis (18). One of these molecules is milk fat globule EGF-factor 8 (MFG-E8)

Methodology Applied

Scientific EffectPhosphatidylserine recognition:

Implementation Method 2

Milk fat globule EGF-factor 8 (MFG-E8) is a potent opsonin for the clearance of apoptotic cells and is produced by mononuclear cells of immune competent organs including the spleen and lungs

Methodology Applied

Scientific EffectOpsonization:

Data Source

PatentUS9018157B2Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8

Publication Date: 2015.04.28 THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH

AI summary

Provided are methods for preventing and treating inflammation and organ injury after ischemia/reperfusion, and methods for treating lung injury, comprising administering a milk fat globule epidermal growth factor-factor VIII (MFG-E8) to a subject. Also provided are pharmaceutical compositions comprising MFG-E8 in dosage form for preventing and treating inflammation and organ injury after ischemia/reperfusion, and for treating lung injury, and methods of preparing a pharmaceutical composition for preventing and treating inflammation and organ injury after ischemia/reperfusion, and for treating lung injury, comprising formulating MFG-E8 in a pharmaceutical composition.